Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old.


Journal

Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 11 8 2018
medline: 20 6 2020
entrez: 11 8 2018
Statut: ppublish

Résumé

Treatment for lung adenocarcinoma frequently diverges from standard treatment in older patients. Clinical, pathologic, and molecular characteristics of lung cancer in patients over 75 years old have not been fully described. The aim of our work was to describe the rate of EGFR, KRAS, BRAF, and HER2 mutations, and ALK rearrangement and pathologic characteristics in patients with lung adenocarcinoma over 75, compared with patients below 75 years old. This is a retrospective study from 2 cohorts: a histopathologic cohort of all consecutively resected lung adenocarcinoma in our institution for patients over 75 (n=54, from 2006 to 2017) compared with patients below 75 years old (n=148, from 2014 to 2017) and a molecular cohort of all stage IIIb or IV lung adenocarcinoma from 2009 to 2017 (n=1611). Papillary and lepidic components were more frequently found in patients over 75 years old (P=0.046 and 0.0078, respectively). The rate of current smokers was lower in older patients (P<0.0001). EGFR mutations were more frequent in patients over 75 than in younger patients: 17% versus 8.1% (P<0.0001). The mutually exclusive KRAS mutation was more frequent in patients below 75 years old than in older patients: 25.8% versus 12.8% (P<0.0001). There was no difference for the proportion of the 2 most frequent EGFR mutations (exon 19 deletion and L858R mutation) (P=0.85) or KRAS-mutated codon (P=0.22) between tumors in younger or older patients. There was no statistically significant difference for the presence of BRAF, HER2 mutations, and ALK rearrangement (P=0.44, 0.71, and 1, respectively). Our work highlights the fact that EGFR mutations are more frequent in patients over 75 years old in our population. We can hypothesize that this difference might be mainly caused by the less frequent occurrence of tobacco-smoking-related lung cancers in the elderly and the presence of a lepidic or papillary component in this age group.

Identifiants

pubmed: 30095461
doi: 10.1097/PAI.0000000000000678
doi:

Substances chimiques

KRAS protein, human 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-671

Auteurs

Fabien Forest (F)

Department of Pathology.
Molecular Analysis of Solid Tumor Department.

Arnaud Patoir (A)

Department of Thoracic Surgery.

Pierre Dal-Col (P)

Department of Pathology.

Vanessa Da Cruz (V)

Department of Pathology.

Florian Camy (F)

Department of Pathology.

Marie-Laure Stachowicz (ML)

Department of Pathology.
Molecular Analysis of Solid Tumor Department.

Sophie Bayle-Bleuez (S)

Department of Pneumology, University Hospital of Saint Etienne, North Hospital, Saint Etienne CEDEX 2.

Pierre Fournel (P)

Department of Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.

Georgia Karpathiou (G)

Department of Pathology.

Michel Péoc'h (M)

Department of Pathology.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH